Ronald S. Go, MD
Idiopathic thrombocytopenic purpura (ITP) is a disorder that can present as bruising or mucosal bleeding, but is usually diagnosed through a process of elimination, explained Ronald S. Go, MD.
Go, an associate professor of medicine at Mayo Clinic, discussed the current treatment strategies of patients with ITP, as well as the process that some physicians use to determine whether a patient is suffering from the disorder.
OncLive: Could you begin by discussing the presentation of ITP?
: The presentation is isolated thrombocytopenia. Of course, patients do not generally come to doctors because they know their platelet counts are low. Mucosal bleeding symptoms and bruising are the initial presentations of ITP. Patients will then have a complete blood count done to look for isolated thrombocytopenia. If there are other cytopenias, anemia, or leukopenia, then we have to look for other possible causes of bicytopenia or pancytopenia. Most often, ITP is [characterized] by low platelets.
We then look at the history to make sure there is nothing else causing the low platelets, such as medications, comorbidities like liver disease, or conditions associated with hypersplenism, all of which can cause thrombocytopenia.
What is the current treatment for these patients?
The first question is, “Who needs treatment?” Generally speaking, it is for those who have platelet counts below 30,000, according to the ASH guidelines. Unless your patient is above 30,000 and is actively bleeding or has symptoms, then we do not treat—we watch. As far as treatment is concerned, most of the time the first-line of treatment is prednisone if there is no contraindication. That works for about 80% of the patients. The platelets will improve, and then we taper them over a couple of weeks. In some patients, that may be the end of it, but in some patients there may be a relapse.
We sometimes use intravenous immunoglobulin (IVIG) if somebody is actively bleeding. IVIG works about two-thirds of the time, but it is temporary and only works for a few days. Dexamethasone can be used as a steroid in the first-line treatment of patients with ITP.
What other kinds of agents are used?
Once the prednisone is used and either the patient does not respond or relapses, the usual second-line treatment is either splenectomy or rituximab. Splenectomy has the best track record in terms of long-term remission; roughly about two-thirds of patients will respond to it. That may be the last treatment for many patients, meaning that it is either curative or it keeps the platelets above 30,000, even though it may not be normal. Rituximab is more frequently used before splenectomy, because it is a nonsurgical treatment. The idea with using rituximab is that it removes the CD20-positive B cells and the antibody-producing cells.
Then, there is a class of drugs that we call the thrombopoietin receptor agonists. They have the ability to stimulate the thrombopoietin receptor, and so the megakaryocytes make more platelets. These drugs are very active, too; about 80% of the time, they work in patients who are refractory to steroids or have at least 1 line of therapy. It works in most cases. The only downside of that treatment is that it does not modify the disease.
... to read the full story